Adverse Reactions to MetroGel for Bacterial Vaginosis
Adverse reactions to metronidazole vaginal gel (MetroGel) for bacterial vaginosis are uncommon and significantly less frequent than with oral metronidazole. The intravaginal formulation achieves less than 2% of the systemic absorption compared to oral dosing, resulting in minimal systemic side effects 1.
Key Safety Profile
Systemic Absorption and Side Effects
The mean peak serum concentrations of metronidazole after intravaginal administration are less than 2% of standard 500-mg oral doses 1. This dramatically reduced bioavailability explains why intravaginal metronidazole gel causes significantly fewer adverse events compared to oral administration 2.
Common Side Effects
Based on the available evidence, the most common adverse reactions with MetroGel include:
- Nasopharyngitis (sore throat and nasal congestion)
- Upper respiratory tract infections
- Headache 3
These occur at rates >2% but are generally mild and self-limited.
Comparative Safety Data
A high-quality randomized, double-blind trial directly comparing intravaginal versus oral metronidazole found:
Intravaginal gel had significantly lower rates of:
- Nausea: 10.2% (intravaginal) vs. 30.4% (oral), p<0.001
- Abdominal pain: 16.8% vs. 31.9%, p<0.01
- Metallic taste: 8.8% vs. 17.9%, p<0.05
- Overall adverse events: significantly less (p=0.023) 2
The intravaginal route maintained equivalent efficacy (92.5% cure rate) while producing substantially better tolerability and patient satisfaction 2.
Serious but Rare Adverse Reactions
Peripheral Neuropathy
While extremely rare with topical use, peripheral neuropathy (tingling, burning, pain, or numbness in hands or feet) has been reported with topical metronidazole 3. This is primarily a concern with systemic metronidazole but warrants immediate discontinuation if neurologic symptoms develop.
Local Reactions
- Vulvar itching can occur with vaginal pessaries 4
- Contact dermatitis is possible but uncommon 3
- Eye irritation/tearing if accidental contact occurs 3
Secondary Infections
One study found that secondary vaginal candidiasis occurred more frequently with suppressive metronidazole gel therapy (p=0.02), though this was in the context of prolonged twice-weekly use rather than standard treatment 5.
Clinical Implications
Treatment Discontinuation
Treatment discontinuation due to adverse effects is rare. One study found only 3% (4/148) of women discontinued oral metronidazole due to side effects 6, and intravaginal gel would be expected to have even lower discontinuation rates given its superior tolerability profile 2.
Pregnancy Considerations
The CDC guidelines note that data are limited concerning the use of metronidazole vaginal gel during pregnancy 1. While systemic metronidazole has not shown teratogenicity in humans 1, the minimal systemic absorption with vaginal gel makes it a reasonable option for patients who cannot tolerate oral therapy, though it's not the first-line recommendation in pregnancy 7.
Important Caveats
Patients allergic to oral metronidazole should NOT be administered metronidazole vaginally due to cross-reactivity risk 1.
Avoid alcohol consumption during treatment and for 24 hours after completion to prevent disulfiram-like reactions 1, 7, 1.
The oil-based formulation of clindamycin cream (an alternative) may weaken latex condoms and diaphragms, but this is not an issue with metronidazole gel 1, 7.
Bottom Line
MetroGel for bacterial vaginosis is well-tolerated with a favorable safety profile. Most adverse reactions are mild (upper respiratory symptoms, headache) and occur at low rates. The dramatic reduction in systemic absorption compared to oral metronidazole translates to significantly fewer gastrointestinal and systemic side effects while maintaining equivalent therapeutic efficacy. This makes intravaginal metronidazole gel an excellent option, particularly for patients who experience side effects with oral therapy.